title: Double-blind multicentre, between patients comparison of indoprofen and indomethacin in rheumatoid arthritis patients under basic steroid treatment.
abstract: The study was aimed at comparing effectiveness, safety and possible steroid sparing effects of indoprofen (800 mg/day) and indomethacin (100 mg/day), in patients with classical or definite rheumatoid arthritis, in active phase, receiving basic steroid treatment at a fixed, not reducible dosage. Treatments were given in double-blind condition, for 1,3 or 6 months, and 97 patients were evaluated. A significant improvement of baseline conditions was obtained with both drugs in all variables considered for evaluation of effectiveness. The initial steroid dosage could be reduced 72% in the indoprofen group and 53% in the indomethacin group; 50% of the patients receiving indoprofen and 22.4% of those receiving indomethacin stopped steroid intake during the trial. Adverse reactions, considered drug related, were observed in 6.7% of patients in the indoprofen group and 34.1% of those given indomethacin.
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007216:Indoprofen / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000627:therapeutic use*; D011897:Random Allocation; D013256:Steroids / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; D013256:Steroids; D007216:Indoprofen; D007213:Indomethacin